INKT MINK THERAPEUTICS INC

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023.

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit  or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.

Investor Contact

917-362-1370

Media Contact

781-674-4428



EN
30/10/2023

Underlying

INKTMINK THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MINK THERAPEUTICS INC

 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Boar...

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors Strengthening Leadership to Accelerate iNKT Therapies into Immune-Mediated Disease, Pulmonary Disorders, and Global Health Security NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Colonel (Ret.) John B. Holcomb, MD, FACS to its Board of Directors. Dr. Holcomb is a globally recognized authority in trauma and critical care, having ...

September 29, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10...

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced that its President and Chief Executive Officer, Dr. Jennifer Buell, will deliver a featured plenary address at the 10th Annual CAR-TCR Summit, taking place September 23–26, 2025, in Boston, MA. The CAR-TCR Summit is one of the industry’s most influential gatherings of academic, c...

September 25, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pi...

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development Imminent launch of grant-funded clinical trial in graft-versus-host disease (GVHD)Advancing clinical program in severe pulmonary inflammatory disease NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural killer T (iNKT) cell therapies, today announced the appointment of Terese C. Hammond, MD as Head of Inflammatory and Pulmonary Diseases, effective immediately. Dr. Hammond is a nationall...

September 18, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second...

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant awarded to launch AgenT-797 in GvHD clinical trial; target initiation 2H2025 NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announc...

August 14, 2025 1 EN
 PRESS RELEASE
Free
INKT MINK THERAPEUTI...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 F...

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2025 financial results before the market opens on Thursday, August 14, 2025. MiNK executives will host a conference call and ...

July 31, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch